PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to…
Earlier this month, FDA approved Boehringer Ingelheim’s high-concentration (100 mg/mL), citrate-free formulation, CYLTEZO (adalimumab-adbm), a biosimilar to Humira (adalimumab). CYLTEZO was first approved in the US in 2017 and later…
According to a May 1, 2024 press release, the high-concentration (100 mg/mL), citrate-free formulation of Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) was approved by the FDA on May 1 as interchangeable with AbbVie’s Humira® …
Drugmakers GSK Plc and Boehringer Ingelheim GmbH prioritized profits over consumer safety by hiding the cancer risks of their once-blockbuster heartburn drug Zantac, according to lawyers representing a Chicago woman in the first of…
Boehringer Ingelheim Pharmaceuticals has manipulated the U.S. patent and drug approval system to unlawfully block makers of generic inhaler medications, health and welfare funds claimed in a lawsuit filed Monday in Connecticut federal…
By using Ochre Bio’s combination computational and multi-omic platform, Boehringer aims to identify, characterize, and validate multiple novel regenerative targets for treatments that can prevent or reverse disease progression by enhancing…
Get latest articles and stories on Business at LatestLY. Mumbai (Maharashtra) [India], April 18: Boehringer Ingelheim, a global leader in animal health, announced the launch of NexGard SPECTRA® (afoxolaner and milbemycin oxime) in India,…
Boehringer Ingelheim, the maker of NexGard® PLUS chews and HEARTGARD® Plus chews, covers medical costs and provides the necessary product to treat asymptomatic heartworm-positive shelter dogs. Air and ground transports for Good Flights…
Boehringer Ingelheim saved its diabetes drug patent from the chopping block after a European appellate board ruled that the treatment for patients with moderately damaged kidneys was new and innovative despite eight oppositions.
Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed BARCELONA, Spain, Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim…
Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed PLEASANTON, Calif., Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer…
INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for…
Enterprise software solution supports drug metabolism and pharmacokinetics groups by digitalizing and automating DMPK operations BASEL, Switzerland, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software…
Boehringer Ingelheim hosted the ‘CRM 360 standalone meeting’, an expert engagement forum, and ‘IMETA CRM Discussions for EXperts (MEDEX)’, a scientific expert meeting
JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of…
DUBLIN, Aug. 23, 2023 The "Global Veterinary Vaccines Market 2023-2029" report has been added to ResearchAndMarkets.com's offering. The global veterinary vaccines market is expected to experience significant growth, reaching a value of $11…